Abeer Al-Habshi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abeer Al-Habshi has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Abdul Khader Mohammed
Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates
1 shared publication Ankita Srivastava
Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates
1 shared publication- Bashair Mohammed Mussa
University of Sharjah
1 shared publication - Rabih Halwani
Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates
1 shared publication - Salah Abusnana
Clinical Science Department, College of Medicine, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates
1 shared publication
Latest Publications
- Open Access
- 1 July 2021
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 14, 3389-3397
Inflammatory Biomarkers Levels in T2DM Emirati Patients with Diabetic Neuropathy
Introduction: Previous studies have suggested the involvement of chronic low‐grade inflammation in the pathogenesis of diabetic neuropathy (DNP). However, none of these studies have examined the levels of monocyte chemoattractant protein-1 (MCP-1) in type 2 diabetes mellitus (T2DM) patients with confirmed diagnosis of neuropathy. Therefore, the present study aims to investigate the levels of MCP-1 along with IL-6, IL-8 and TGF-β in patients with T2DM and confirmed neuropathy and identify correlations, if any, between MCP-1 and other parameters. Methods: A single center cross-sectional clinical study was conducted at University Hospital Sharjah (UHS) and University of Sharjah. One hundred and two patients with T2DM were recruited from diabetes clinics at UHS and were stratified into different groups based on diagnosis of DNP and other parameters. Several analyses were conducted to evaluate and compare the levels of MCP-1, IL-6, IL-8, and TGF-β across these groups of patients and identify correlations, if any, between MCP-1 and other variables. Results: A significant increase was found in the levels of MCP-1 in T2DM patients with DNP compared to the patients without DNP (p=0.002, p-adj=0.007). Further analysis has shown that levels of IL-8 (p=0.008) and TGF-β (p=0.06) were increased and decreased, respectively, in patients with DNP compared to patients without DNP. Moreover, strong correlations were found between MCP-1, IL-8 and TGF-β levels. Conclusion: The key finding of the present study is the significant elevation in levels of MCP-1 in T2DM patients with DNP compared to the patients without DNP and IL-8 and TGF-β were strong predictors of MCP-1 increased levels.
- 1 July 2021
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 14, 3389-3397
Open AccessInflammatory Biomarkers Levels in T2DM Emirati Patients with Diabetic Neuropathy
Introduction: Previous studies have suggested the involvement of chronic low‐grade inflammation in the pathogenesis of diabetic neuropathy (DNP). However, none of these studies have examined the levels of monocyte chemoattractant protein-1 (MCP-1) in type 2 diabetes mellitus (T2DM) patients with confirmed diagnosis of neuropathy. Therefore, the present study aims to investigate the levels of MCP-1 along with IL-6, IL-8 and TGF-β in patients with T2DM and confirmed neuropathy and identify correlations, if any, between MCP-1 and other parameters. Methods: A single center cross-sectional clinical study was conducted at University Hospital Sharjah (UHS) and University of Sharjah. One hundred and two patients with T2DM were recruited from diabetes clinics at UHS and were stratified into different groups based on diagnosis of DNP and other parameters. Several analyses were conducted to evaluate and compare the levels of MCP-1, IL-6, IL-8, and TGF-β across these groups of patients and identify correlations, if any, between MCP-1 and other variables. Results: A significant increase was found in the levels of MCP-1 in T2DM patients with DNP compared to the patients without DNP (p=0.002, p-adj=0.007). Further analysis has shown that levels of IL-8 (p=0.008) and TGF-β (p=0.06) were increased and decreased, respectively, in patients with DNP compared to patients without DNP. Moreover, strong correlations were found between MCP-1, IL-8 and TGF-β levels. Conclusion: The key finding of the present study is the significant elevation in levels of MCP-1 in T2DM patients with DNP compared to the patients without DNP and IL-8 and TGF-β were strong predictors of MCP-1 increased levels.